Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Imperial College, London
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cardiac Arrest
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2018-000005-23 |
Ghrelin in coma | P2 |
Active, not recruiting |
Cardiac Arrest |
2020-12-12 |
2025-07-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/07/2026 |
News Article |
Oxeia Pioneering First Potential FDA-Approved Concussion Treatment |
|
01/07/2026 |
News Article |
/C O R R E C T I O N -- Oxeia Biopharmaceuticals, Inc./ |
|
12/01/2025 |
News Article |
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore |
|
10/16/2025 |
News Article |
Umbrella Labs Launches Research Brief Series With GW-501516, RAD-140, and MK-677 Added to 2025 Investigational Catalog |
|
05/15/2024 |
PubMed |
Ghrelin deletion and conditional ghrelin cell ablation increase pancreatic islet size in mice. |
|
05/13/2024 |
PubMed |
Obesity and Depression: Common Link and Possible Targets. |
|
03/13/2024 |
PubMed |
A bird's-eye overview of molecular mechanisms regulating feed intake in chickens-with mammalian comparisons. |